Reduction in tumor correlates to proliferation of CD8+ TILs. Association of CD8+ TILs at the invasive margin of met. SKCM tumors and clinical benefit. Less diverse TCR repertoire associated with a better outcome. This evidence concerns the gene CD8A and neoplasm.